Equities Analysts Offer Predictions for AVDL FY2025 Earnings

Avadel Pharmaceuticals plc (NASDAQ:AVDL) – Equities research analysts at Leerink Partnrs reduced their FY2025 earnings per share estimates for shares of Avadel Pharmaceuticals in a report issued on Tuesday, November 12th. Leerink Partnrs analyst M. Goodman now expects that the company will earn $0.95 per share for the year, down from their previous estimate of $1.05. The consensus estimate for Avadel Pharmaceuticals’ current full-year earnings is ($0.50) per share. Leerink Partnrs also issued estimates for Avadel Pharmaceuticals’ FY2026 earnings at $2.00 EPS and FY2028 earnings at $3.15 EPS.

Avadel Pharmaceuticals (NASDAQ:AVDL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.03. The company had revenue of $50.00 million for the quarter, compared to analyst estimates of $48.43 million. Avadel Pharmaceuticals had a negative net margin of 52.53% and a negative return on equity of 92.12%. The company’s quarterly revenue was up 624.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.41) earnings per share.

Other equities analysts have also recently issued reports about the company. Oppenheimer lifted their price target on Avadel Pharmaceuticals from $29.00 to $30.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price target on shares of Avadel Pharmaceuticals in a research report on Tuesday. Finally, HC Wainwright cut their price objective on shares of Avadel Pharmaceuticals from $27.00 to $25.00 and set a “buy” rating for the company in a research report on Wednesday. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $24.43.

Avadel Pharmaceuticals Trading Down 3.6 %

Avadel Pharmaceuticals stock opened at $11.59 on Thursday. The firm has a 50 day simple moving average of $13.62 and a 200 day simple moving average of $15.09. Avadel Pharmaceuticals has a 1-year low of $10.39 and a 1-year high of $19.09. The firm has a market capitalization of $1.12 billion, a price-to-earnings ratio of -14.67 and a beta of 1.47.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. FMR LLC bought a new stake in Avadel Pharmaceuticals during the third quarter valued at approximately $31,000. Amalgamated Bank bought a new position in Avadel Pharmaceuticals in the second quarter valued at $45,000. BNP Paribas Financial Markets raised its position in Avadel Pharmaceuticals by 60.5% during the first quarter. BNP Paribas Financial Markets now owns 4,469 shares of the company’s stock valued at $75,000 after purchasing an additional 1,685 shares in the last quarter. Quarry LP purchased a new position in shares of Avadel Pharmaceuticals in the 2nd quarter worth about $63,000. Finally, Advisors Asset Management Inc. increased its position in shares of Avadel Pharmaceuticals by 56.1% during the 3rd quarter. Advisors Asset Management Inc. now owns 7,921 shares of the company’s stock valued at $104,000 after purchasing an additional 2,846 shares during the last quarter. Hedge funds and other institutional investors own 69.19% of the company’s stock.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.